Immunologic Changes after Rush Allergen-Specific Immunotherapy in Childre

Not Applicable

• Conditions: Children with allergic diseases: AR, Asthma, AD, insect bite anaphylaxis; Tregs; immunotherapy; RIT

• Registration Number: TCTR20170825001
• Lead Sponsor: Faculty of Medicine Ramathibodi Hospital, Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-25
• Study Completion: 2018-05-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

children with AR, AD, Asthma, or insect bite anaphylaxis

Exclusion Criteria

uncontrolled asthma
receiving or just stop other immunotherapy in the past 5 years
underlying diseases: cardiovascular diseases, malignancy
have current medications: beta-blocker, ACEI

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changing of regulatory T cells before start immunotherapy, after rush schedules, after reaching maintenance dose, and 6-month later percentage of CD4+CD25+FOXP3+ T cells in total CD4+ T cells

Secondary Outcome Measures

Name	Time	Method
clinical of allergic rhinitis before start immunotherapy, after reaching maintenance dose, and 6-month later allergic rhinitis symptom-free day,clinical of atopic dermatitis before start immunotherapy, after reaching maintenance dose, and 6-month later SCORAD scales